BOOTS/HOECHST CELANESE TO COLLABORATE ON BULK IBUPROFEN

BOOTS/HOECHST CELANESE TO COLLABORATE ON BULK IBUPROFEN production in the U.S. via a 50/50 joint venture, the companies announced in an April 21 press release. "The partners expect to install in the United States a commercial facility which will use Hoechst Celanese technology. The facility is expected to come on stream in 1991," the two companies said. An ibuprofen production line will be built in one of Hoechst Celanese's three existing manufacturing plants in Texas. The installation of the ibuprofen manufacturing line is expected to require capital costs of $ 35 mil., the companies noted. The new plant will have the capacity to produce 2,500 metric tons of bulk ibuprofen annually, Boots predicted. Boots, which discovered ibuprofen, currently supplies the worldwide market for bulk ibuprofen from a 3,000-ton-per-year facility in Nottingham, England, the company said. The Nottingham plant provides bulk ibuprofen to Boots Pharmaceuticals in Shreveport, Louisiana for the production of Rufen and to American Home Products for the manufacture of Advil. Boots used to supply Upjohn with bulk ibuprofen. Boots' primary competitor in the U.S. bulk ibuprofen market is Ethyl Corp., which is currently the only U.S. manufacturer of bulk ibuprofen. Ethyl also exports its bulk ibuprofen. Ethyl noted that it will soon have the capacity to produce over 2,300 metric tons of ibuprofen annually.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

Ocaliva: Still No Clarity On Why EU Court Opposed Revocation Of Approval

 

Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By 

This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By 

We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.

Brazil Pilots Digital Drug Pack Inserts

 

A new pilot aims to take Brazil closer to ‘digital transformation.’

More from Pink Sheet

EMA Backs Gilead’s Yeytuo And 13 Other Drugs For EU Approval But Rejects Three

 

The European Medicines Agency’s human medicines committee, the CHMP, has recommended 14 new medicines for pan-EU approval this month, including five orphan medicines.

Lilly Wins EU Thumbs Up For Kisunla After EMA Reverses Rejection

 

The European Medicines Agency says that Eli Lilly's Alzheimer's disease drug should be approved for use in the EU, now that it has re-examined the negative opinion it previously adopted.

EMA Says ‘No’ To Roche/Sarepta’s Elevidys, US FDA Investigates Fourth Death

 

The European Medicines Agency recommended against pan-EU marketing authorization of Roche/Sarpeta’s gene therapy Elevidys for the treatment of Duchenne muscular dystrophy as the US reported another death in an Elevidys patient.